GSK and Curevac have signed an mRNA vaccine and monoclonal antibody drug manufacturing and commercialization agreement. The agreement will combine Curevac’s mRNA technology and manufacturing capabilities with GSK’s vaccines knowhow, self-amplifying mRNA (SAM) vaccine technology platform as well as its monoclonal antibody development and production capacity. The collaboration will focus on five mRNA-based vaccines and mAbs targeting infectious diseases. GSK has agreed to pay €120 million upfront and make an equity investment of €150 million in Curevac. The programs do…